GladysIRodriguezMD

PubMed

• American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care.
  Nathan A. Pennell, Melissa S. Dillmon, Laura A. Levit, E. Allyn Moushey, Ajjai Alva, Sibel Blau, Timothy L. Cannon, Natalie R. Dickson, Maximilian Diehn, Mithat Gonen,...> ;Journal of Clinical Oncology. 2021 Jan 10
• TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.
  Denise A. Yardley, Edward Arrowsmith, Brooke R. Daniel, J. F. Eakle, Adam Brufsky, David Drosick, Fred J. Kudrik, Linda D. Bosserman, Mark Keaton, Sharon A. Goble, Jef...> ;Breast Cancer Research and Treatment. 2017 May 15
• Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer.
  Leticia Batista Azevedo Rangel, Jodi L. Taraba, Christopher R. Frei, Lon Smith, Gladys Rodriguez, John G. Kuhn> ;Breast Cancer Research and Treatment. 2014 Nov 14
• Carcinoma of Unknown Primary Site: Sequential Treatment with Paclitaxel/Carboplatin/Etoposide and Gemcitabine/Irinotecan: A Minnie Pearl Cancer Research Network Phase ...
  F. Anthony Greco, G. I. Rodriguez, Don W. Shaffer, Robert C. Hermann, Sharlene Litchy, Denise A. Yardley, Howard A. Burris, Lisa H. Morrissey, Joan B. Erland, John D. ...> ;Oncologist. 2004 Nov 1
• Weekly paclitaxel/estramustine phosphate plus carboplatin administered either weekly or every 4 weeks in the treatment of hormone refractory prostate cancer (HRPC): A ...
  Meluch AA, Greco FA, Burris HA, Erland JB, Khan RA, Rodriguez GI, Gandhi JG, Hainsworth JD> ;J. Clin. Oncol.. 2004-07-15
• First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial.
  John D. Hainsworth, Sharlene Litchy, M. Ray Lamb, G. I. Rodriguez, Jr. Carroll Scroggin, F. Anthony Greco> ;Clinical Lymphoma, Myeloma & Leukemia. 2003 Jun 1
• Phase I Clinical Trials of Tezacitabine [(E)-2′-Deoxy-2′-(fluoromethylene)cytidine] in Patients with Refractory Solid Tumors
  Gladys Rodriguez, Richard E. Jones, Elaine K. Orenberg, Maxine L. Stoltz, Donald J. Brooks> ;Clinical Cancer Research. 2002 Sep 1
• Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
  Rothenberg ML, Kuhn JG, Schaaf LJ, Rodriguez GI, Eckhardt SG, Villalona-Calero MA, Rinaldi DA, Hammond LA, Hodges S, Sharma A, Elfring GL, Petit RG, Locker PK, Miller ...> ;Ann. Oncol.. 2001-11-01
• A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.
  Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R, Robertson AG, Park O, Gulley ML, Heise C, Von Hoff DD, Kaye SB, Eckhardt SG> ;Clin. Cancer Res.. 2000-03-01
• Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies
  Manuel Hidalgo, Miguel A. Villalona-Calero, S. Gail Eckhardt, Ronald Drengler, Gladys Rodriguez, Lisa A. Hammond, Sami Diab, Geoffrey R. Weiss, Allison M. Garner, E. C...> ;Journal of Clinical Oncology. 2000 Jan 1
• A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
  David Rinaldi, John G. Kuhn, Howard A. Burris, F. Andrew Dorr, Gladys Rodriguez, S. Gail Eckhardt, Suzanne F. Jones, James R. Woodworth, Sharyn D. Baker, Connie Langle...> ;Cancer Chemotherapy and Pharmacology. 1999 Oct 7
• Phase II trial of docetaxel for cholangiocarcinoma.
  Richard Pazdur, Melanie Royce, Gladys Rodriguez, David Rinaldi, Yehuda Z. Patt, Paulo M. Hoff, Howard A. Burris> ;American Journal of Clinical Oncology. 1999 Feb 1
• Phase I and Pharmacokinetic Trial of Oral Irinotecan Administered Daily for 5 Days Every 3 Weeks in Patients With Solid Tumors
  Ronald Drengler, John G. Kuhn, Larry J. Schaaf, Gladys Rodriguez, Miguel A. Villalona-Calero, Lisa A. Hammond, J. Stephenson, Stephanie Hodges, Maura Kraynak, Brian A....> ;Journal of Clinical Oncology. 1999 Feb 1
• A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
  Sami Diab, Sharyn D. Baker, Amita S. Joshi, Howard A. Burris, Patrick W. Cobb, Miguel A. Villalona-Calero, S. Gail Eckhardt, Geoffrey R. Weiss, Gladys Rodriguez, Ronal...> ;Clinical Cancer Research. 1999 Feb 1
• A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
  Gerrits CJ, Schellens JH, Burris H, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Von Hoff DD, Verweij J> ;Clin. Cancer Res.. 1999-01-01
• A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.
  Hidalgo M, Rodriguez G, Kuhn JG, Brown T, Weiss G, MacGovren JP, Von Hoff DD, Rowinsky EK> ;Clin. Cancer Res.. 1998-11-01
• Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors
  M. L. Rothenberg, A. Sharma, Geoffrey R. Weiss, Miguel A. Villalona-Calero, J. R. Eckardt, C. Aylesworth, M. A. Kraynak, David Rinaldi, Gladys Rodriguez, H. A. Burris,...> ;Annals of Oncology. 1998 Jul 1
• Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.
  Gerrits CJ, Burris H, Schellens JH, Planting AS, van den Burg ME, Rodriguez GI, van Beurden V, Loos WJ, Hudson I, Fields S, Verweij J, von Hoff DD> ;Eur. J. Cancer. 1998-06-01
• Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
  C. J. H. Gerrits, H. A. Burris, J. H. M. Schellens, J. R. Eckardt, A. S. T. Planting, M.E.L. van der Burg, G. I. Rodriguez, Walter J. Loos, V. van Beurden, I. Hudson, ...> ;Clinical Cancer Research. 1998 May 1
• A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea
  Gladys Rodriguez, John G. Kuhn, Geoffrey R. Weiss, Susan G. Hilsenbeck, John R. Eckardt, Allison Thurman, David Rinaldi, Stephanie Hodges, Daniel D. Von Hoff, Eric K. ...> ;Blood. 1998 Mar 1
• Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
  Eckhardt SG, Baker SD, Eckardt JR, Burke TG, Warner DL, Kuhn JG, Rodriguez G, Fields S, Thurman A, Smith L, Rothenberg ML, White L, Wissel P, Kunka R, DePee S, Littlef...> ;Clin. Cancer Res.. 1998-03-01
• Phase I study with the DNA sequence-specific agent adozelesin.
  Howard A. Burris, Véronique Diéras, Mehmet Tunca, Robert H. Earhart, John R. Eckardt, Gladys Rodriguez, Donald S Shaffer, Suzanne M. Fields, E. Campbell, Larry J. Scha...> ;Anti-Cancer Drugs. 1997 Jul 1
• Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
  G. J. Creemers, C. J. H. Gerrits, J. R. Eckardt, J. H. M. Schellens, H. A. Burris, A. S. T. Planting, G. I. Rodriguez, Walter J. Loos, I. Hudson, C. Broom, J. Verweij,...> ;Journal of Clinical Oncology. 1997 Mar 1
• New anticancer agents.
  Weiss GR, Burris HA, Eckhardt SG, Rodriguez GI, Sharma S, Valley A> ;Cancer Chemother Biol Response Modif. 1997-01-01
• A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium.
  Eckhardt SG, Burris HA, Eckardt JR, Weiss G, Rodriguez G, Rothenberg M, Rinaldi D, Barrington R, Kuhn JG, Masuo K, Sudo K, Atsumi R, Oguma T, Higashi L, Fields S, Smet...> ;Ann. Oncol.. 1996-07-01
• Join now to see all